Initiation of Treatment With SGLT2 Inhibitors and GLP-1 Receptor Agonists According to the Level of Frailty in People With Type 2 Diabetes and CVD in Denmark
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study
Lancet 2023 Sep 18;[EPub Ahead of Print], ME Malik, JH Butt, JE Strange, AC Falkentoft, J Jensen, C Andersson, D Zahir, E Fosbøl, MC Petrie, N Sattar, JJV McMurray, L Køber, M SchouFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.